ResearcherScience for Life LaboratoryActive in the last 2 years

Emma Eriksson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8710-7307; OpenAlex author ID A5109802041. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): resul… Co-author DOI 10.1016/s1470-2045(24)00079-2 ↗
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. Co-author DOI 10.1186/s12967-016-1037-z ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Angelica Loskog · 2 shared papers, 2016–2024 · strength 0.24
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
- Paper Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. DOI 10.1186/s12967-016-1037-z ↗
Gustav Jörgen Ullenhag · 2 shared papers, 2016–2024 · strength 0.24
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
- Paper Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer. DOI 10.1186/s12967-016-1037-z ↗
Ann Marie Leen · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Eric Keith Rowinsky · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Linda C. Sandin · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Mohamed O. Othman · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Brandon George Smaglo · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗
Benjamin Musher · 1 shared paper, 2024 · strength 0.16
- Paper LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metast… DOI 10.1016/s1470-2045(24)00079-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.